Collagen News and Research

Latest Collagen News and Research

RegeneRx Biopharmaceuticals completes Phase I trial evaluating systemic administration of RGN-352

RegeneRx Biopharmaceuticals completes Phase I trial evaluating systemic administration of RGN-352

New study utilizes solid-state NMR spectroscopy to analyze intact bone

New study utilizes solid-state NMR spectroscopy to analyze intact bone

CCII capsules offer safe and effective treatment for rheumatoid arthritis

CCII capsules offer safe and effective treatment for rheumatoid arthritis

Enzyme that plays an important role in the formation of breast tumours identified

Enzyme that plays an important role in the formation of breast tumours identified

U.S. Court rules in Merck's favor in Flemings case involving FOSAMAX

U.S. Court rules in Merck's favor in Flemings case involving FOSAMAX

Discovery of Th22 cells may help in developing effective therapies for chronic skin and respiratory diseases

Discovery of Th22 cells may help in developing effective therapies for chronic skin and respiratory diseases

New non-surgical procedure to improve body contours

New non-surgical procedure to improve body contours

Green tea prevents the development of hepatic fibrosis in rat model of DMN-induced liver fibrosis

Green tea prevents the development of hepatic fibrosis in rat model of DMN-induced liver fibrosis

Targeting normal cells that surround cancer cells increases the effectiveness of traditional anti-cancer treatments

Targeting normal cells that surround cancer cells increases the effectiveness of traditional anti-cancer treatments

Platelet function tests predict heart attacks in patients pre-treated with two anti-clotting medications before coronary stenting

Platelet function tests predict heart attacks in patients pre-treated with two anti-clotting medications before coronary stenting

Suneva Medical commends Trilogy Education for conducting a two-day dermal filler training course for nurses

Suneva Medical commends Trilogy Education for conducting a two-day dermal filler training course for nurses

arGentis Pharmaceuticals to commence human clinical evaluation of ARG301 oral altered peptide ligand

arGentis Pharmaceuticals to commence human clinical evaluation of ARG301 oral altered peptide ligand

FDA regulatory clearance for Kensey Nash's ECM product

FDA regulatory clearance for Kensey Nash's ECM product

TivaMed changes its name to Viveve

TivaMed changes its name to Viveve

BioSpecifics Technologies revenues increases by 100% for the third quarter ended September 30, 2009

BioSpecifics Technologies revenues increases by 100% for the third quarter ended September 30, 2009

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Study demonstrates potential of human Serum Amyloid P to block very aggressive fibrotic pathology

Study demonstrates potential of human Serum Amyloid P to block very aggressive fibrotic pathology

EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

Cardium Therapeutics to seek FDA marketing clearance for ExcellagenXL

Cardium Therapeutics to seek FDA marketing clearance for ExcellagenXL

Helix BioMedix' SmartPeptides technology products demonstrate improvement in skin texture

Helix BioMedix' SmartPeptides technology products demonstrate improvement in skin texture

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.